tbuckley/cabot-search huggingface dataset:
Changes in Socioeconomic, Racial/Ethnic, and Sex Disparities in Childhood Obesity at School Entry in the United States
Authors: Ashlesha Datar, Paul J. Chung
Journal: JAMA Pediatrics (2015)

The National Health and Nutrition Examination Survey data suggest a plateauing of childhood obesity in the United States, with no trend among children younger than 11 years since 1999. 1,2However, studies have challenged this finding and cautioned that the overall static trend masks significant differences across subgroups. 3,4There is not much consensus about whether and how childhood obesity prevalence has changed for various age, sex, race/ethnicity, and socioeconomic subgroups. 2,4Available data on 2 nationally representative cohorts of US kindergarten-aged children 12 years apart provide a valuable opportunity to document changes in weight gain and obesity among young children and underlying sex, socioeconomic, and racial/ethnic disparities between 1998 and 2010.
Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma
Authors: A. Perry, B.J. Vincent, S.R.S. Parker
Journal: British Journal of Dermatology (2010)

Journal Article Intralesional corticosteroid therapy for primary cutaneous B‐cell lymphoma Get access A. Perry, A. Perry Department of Dermatology, Emory University Medical School and Grady Memorial Hospital, 1365 Clifton Road NE, Building A, Suite 1100, Atlanta, GA 30322, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar B.J. Vincent, B.J. Vincent Department of Dermatology, Emory University Medical School and Grady Memorial Hospital, 1365 Clifton Road NE, Building A, Suite 1100, Atlanta, GA 30322, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar S.R.S. Parker S.R.S. Parker Department of Dermatology, Emory University Medical School and Grady Memorial Hospital, 1365 Clifton Road NE, Building A, Suite 1100, Atlanta, GA 30322, U.S.A. Sareeta R.S. Parker E‐mail: srsingh@emory.edu Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 163, Issue 1, 1 July 2010, Pages 223–225, https://doi.org/10.1111/j.1365-2133.2010.09798.x Published: 01 July 2010
Abnormal Coronary Vasomotion in Hypertension: Role of Coronary Artery Disease11This study was supported by the Swiss National Science Foundation, Bern, Switzerland.
Authors: JÜRGEN FRIELINGSDORF, PHILIPP KAUFMANN, CHRISTIAN SEILER, GIUSEPPE VASSALLI, THOMAS SUTER, OTTO M HESS
Journal: Journal of the American College of Cardiology (1996)
Effects of Autoantibodies to the Insulin Receptor on Isolated Adipocytes
Authors: C. Ronald Kahn, Kathleen Baird, Jeffrey S. Flier, David B. Jarrett
Journal: Journal of Clinical Investigation (1977)

Autoantibodies to the insulin receptor have been detected in the sera of several patients with the Type B syndrome of insulin resistance and acanthosis nigricans. In this study we have used three of these sera (B-1, B-2, and B-3) as probes of the insulin receptor in isolated rat adipocytes. Preincubation of adipocytes with each of the three sera resulted in an inhibition of subsequent [(125)I]insulin binding. 50% inhibition of binding occurred with serum dilutions of 1:5 to 1:7,500. As in our previous studies with other tissues, Scatchard analysis of the insulin-binding data was curvilinear consistent with negative cooperativity. Computer analysis suggested that in each case the inhibition of binding was due to a decrease in receptor affinity rather than a change in available receptor number. In addition to the effects on insulin binding, adipocytes pretreated with antireceptor sera also showed alterations in biological responses. All three sera produced some stimulation of basal glucose oxidation. With serum B-3, maximal stimulation of glucose oxidation occurred at a serum concentration that inhibited binding by only 10-15%, whereas with serum B-2 the dilution curves for inhibition of binding and stimulation of glucose oxidation were superimposable. Serum B-1 behaved as a partial agonist; that is, it inhibited binding more effectively than it stimulated glucose oxidation. Cells pretreated with this serum in a concentration which inhibited binding by 80% also showed a five-fold shift to the right in the dose response of insulin-stimulated glucose oxidation, whereas spermine-stimulated glucose oxidation was unaffected. Serum B-2, which contained the highest titer of antireceptor antibodies, also stimulated 2-deoxy-glucose transport, as well as glucose incorporation into lipid and glycogen. Both the ability of the serum to inhibit binding and stimulate glucose utilization were enriched in purified immunoglobulin fractions and retained in the F(ab')(2) fragment of the IgG. In addition, the bioactivity was blocked by antihuman IgG but not by anti-insulin antibodies. Enzymatic digestion of adipocytes with trypsin resulted in a complete loss of insulin-stimulated bioactivity of serum B-3, but had only minor effects on the glucose oxidation produced by serum B-1 or B-2.These data suggest that the antibodies present in these three sera bind to different determinants on the insulin receptor. Thus, these antibodies may be useful probes of receptor structure and function.
Abstract 12600: Microrna From Atrial Tissue Harvested During Transseptal Puncture as a Predictor for Non-pv Trigger in Patients Undergoing Af Ablation: Preliminary Results From a Pilot Study
Authors: Luigi Di Biase, Aaron Baker, Xue Yan, Jason Lee, Francesco Santoro, Chintan Trivedi, Sanghamitra Mohanty, Prasant Mohanty, Rong Bai, Javier Sanchez, Rodney Horton, G. Joseph Gallinghouse, J. David Burkhardt, Andrea Natale
Journal: Circulation (2014)

Introduction: Catheter ablation of atrial fibrillation (AF) is the most valid therapeutic option to achieve rhythm control. Pulmonary veins (PV) are the most known trigger of AF, although recently we have become more aware of the importance of non-PV triggers. Expression of microRNA (miRNA) has been shown to be regulated in many cardiovascular disease. We sought to study expression patterns of miRNA in patients (pts) with AF undergoing ablation to facilitate their application as both diagnostic and prognostic markers. Methods: As part of the standard procedure for AF ablation a double transseptal sample of myocardial tissue is obtained via a transseptal needle. The small piece of atrial septal tissue can be retrieved from the needle as a result of piercing the atrial septum. MiRNA was hybridized to microarrays to determine relative levels of miRNAs in the samples. For a subset of the miRNAs we validated expression through quantitative real time PCR. All pts underwent PV-antrum and non-PV trigger ablation guided by isoproterenol challenge test. Results: Atrial tissue of 11 pts undergoing AF ablation has been utilized for MiRNA assessment. Mean age was 61.27 ± 10.5 years and 8 (72.7%) pts were male. Six (54.5 %) pts had paroxysmal AF. During the ablation non-PV triggers were detected in 8 (72.7 %) pts. Recurrence of AF occurred in 3(27.3 %) pts. Expression of miR-21, miR-26a and miR-29a was higher in pts with non-PV triggers, while miR-30c had lower expression in pts who had recurrence of atrial tachyarrhythmias. Spearman’s nonparametric correlation coefficient was calculated and miR-21, miR-26a, miR-29a were positively correlated with non-PV triggers (r = 0.58, p=0.06 for all three miRNAs), while miR-30c level had inverse correlation (r = (-) 0.78 %, p=0.005) with recurrence (Figure). Conclusions: Expression of miR-21, miR-26a, miR-29a correlates with the presence of non-PV triggers. This information could be clinically relevant in planning patient specific procedures.
<i>BCR/ABL</i> level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase
Authors: Dennis (Dong Hwan) Kim, Nada Hamad, Hong Gi Lee, Suzanne Kamel‐Reid, Jeffrey H. Lipton
Journal: American Journal of Hematology (2014)

It is unclear if patients with CML treated with imatinib who fail to achieve BCR/ABL transcript levels <10%(IS) at 3 months i.e. an early molecular response (EMR) have a better prognosis if they achieve a response by 6 months. We reviewed 320 patients with chronic myeloid leukemia (CML) in chronic phase receiving Imatinib therapy with 3 and 6 month BCR/ABL transcript levels available, and divided them into four groups. Group I (achieved an EMR at 3 months), Group II (did not achieve an EMR at 3 months, but achieved a transcript level of <1% at 6 months), Group III (did not achieve an EMR at 3 months, then at 6 months achieved a level between 1% and 10%) and Group IV (failed to achieve a response at 3 and 6 months). Compared to Group I, Group IV showed significantly worse freedom from treatment failure (FTF; 93.1% vs 69.0%, P < 0.001), progression free survival (97.7% vs 77.3%, P < 0.001) and overall survival (98.3% vs 78.9%, P < 0.001). While, group III showed inferior PFS (98.3% vs 90.4%, P = 0.013) and OS (97.7% vs 90.4%, P = 0.037), but no difference in FTF (93.1% vs 92.0%, P = 0.520). There were no significant differences between Groups I and II. A BCR/ABL transcript level at 6 months can identify a "good-risk" subgroup among patients who fail to achieve an EMR on Imatinib therapy for CML.
Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis
Authors: M. Der-Petrossian, A. Seeber, H. Hönigsmann, A. Tanew
Journal: British Journal of Dermatology (2000)

Journal Article Half‐side comparison study on the efficacy of 8‐methoxypsoralen bath‐PUVA versus narrow‐band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis Get access M. Der‐Petrossian, M. Der‐Petrossian Department of Dermatology, Division of Special and Environmental Dermatology, University of Vienna Medical School, Währinger Gürtel 18–20, A‐1090 Vienna, Austria Manon Der‐Petrossian.E‐mail: manon.der‐petrossian@akh‐wien.ac.at Search for other works by this author on: Oxford Academic Google Scholar A. Seeber, A. Seeber Division of Dermatology, Sozialmedizinisches Zentrum Ost, Vienna, Austria Search for other works by this author on: Oxford Academic Google Scholar H. Hönigsmann, H. Hönigsmann Department of Dermatology, Division of Special and Environmental Dermatology, University of Vienna Medical School, Währinger Gürtel 18–20, A‐1090 Vienna, Austria Search for other works by this author on: Oxford Academic Google Scholar A. Tanew A. Tanew Department of Dermatology, Division of Special and Environmental Dermatology, University of Vienna Medical School, Währinger Gürtel 18–20, A‐1090 Vienna, Austria Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 142, Issue 1, 1 January 2000, Pages 39–43, https://doi.org/10.1046/j.1365-2133.2000.03239.x Published: 01 January 2000
Predictive value for weakness and 1-year mortality of screening electrophysiology tests in the ICU
Authors: Greet Hermans, Helena Van Mechelen, Frans Bruyninckx, Tine Vanhullebusch, Beatrix Clerckx, Philippe Meersseman, Yves Debaveye, Michael P. Casaer, Alexander Wilmer, Pieter J. Wouters, Ilse Vanhorebeek, Rik Gosselink, Greet Van den Berghe
Journal: Intensive Care Medicine (2015)
Abstract 1912: Neural Cell Adhesion Molecule is a Cardioprotective Factor Upregulated by Metabolic Stress
Authors: Kazuya Nagao, Koh Ono, Takahiro Horie, Hitoo Nishi, Minako Kinoshita, Yoji Kojima, Yodo Tamaki, Yasuhide Kuwabara, Yoshitaka Iwanaga, Toru Kita, Takeshi Kimura
Journal: Circulation (2009)

Purpose:  The failing heart is characterized by alterations in energy metabolism. To screen for cell-surface proteins showing enhanced expression under metabolic stress, we performed a signal sequence trap in combination with a functional cloning method.   Methods and results:  We screened for cell-surface proteins showing enhanced expression using oligomycin, a mitochondorial inhibitor in H9C2 rat cardiac myoblasts. One of the identified genes was neural cell adhesion molecule (NCAM). In H9C2 and primary rat cardiac myocytes, oligomycin treatment significantly upregulated the mRNA and protein level of NCAM in a p38-dependent manner, whereas phenylephrine and AT-II did not. To analyze the expression pattern of NCAM in diseased hearts in vivo, we examined the NCAM expression in a mouse MI model. mRNA was upregulated 15.2±0.20 fold in the infarcted area (P   Conclusion:  NCAM may play a protective role in the metabolically stressed heart and may be available as a new therapeutic target.
The Role of Mig, the Monokine Induced by Interferon-γ, and IP-10, the Interferon-γ–Inducible Protein-10, in Tissue Necrosis and Vascular Damage Associated With Epstein-Barr Virus-Positive Lymphoproliferative Disease
Authors: Julie Teruya-Feldstein, Elaine S. Jaffe, Parris R. Burd, Hirokazu Kanegane, Douglas W. Kingma, Wyndham H. Wilson, Dan L. Longo, Giovanna Tosato
Journal: Blood (1997)
Oncolytic virotherapy for targeting ovarian cancer using fully folate receptor targeted recombinant measles virus
Authors: Kosei Hasegawa, Takafumi Nakamura, Mary Harvey, Atsushi Hongo, Mariangela Figini, Silvana Canervari, Kah-Whye Peng
Journal: Cancer Research (2006)

4019   We have shown that the MV-Edm, a vaccine strain of measles virus, is potently oncolytic for many types of tumor cells but causes minimal damage on normal cells. Phase I clinical trial in ovarian cancer using recombinant measles virus which express soluble CEA for non-invasive monitoring of viral gene expression is on-going in our institution. We are continuing to improve the efficacy and specificity of oncolytic measles virotherapy for ovarian cancer. Folate receptor alpha (FR alpha) is overexpressed in 90% of ovarian cancer but is absent in most adult somatic tissues, making FR alpha an attractive tumor selective target for ovarian cancer. To generate a fully retargeted virus, measles H interaction with viral receptors CD46 and SLAM was eliminated by alanine substitution at residues 481 and 533 of measles H protein. To target virus entry and cell fusion exclusively to FR alpha ovarian cancer cells, we cloned MOv18, a scFv against FR alpha, onto measles H and rescued MV-MOv18, the fully FR alpha retargeted measles virus. MV-MOv18 specifically infected and caused extensive fusion in FR alpha expressing cells. In contrast to parental MV-GFP, MV-MOv18 showed only background infection in normal cells. Specificity of MV-MOv18 for FR alpha tumors was also demonstrated  in vivo . Intraperitoneal administration of MV-GFP to measles susceptible CD46 transgenic mice resulted in the virus being trapped by peritoneal macrophages, but not MV-MOv18. These results showed that MV-MOv18 is promising oncolytic virus for ovarian cancer virotherapy.
Abstract 16912: Angioplasty vs. primary nitinol stent implantation in above knee femoropopliteal occlusive atherosclerotic disease: a meta-analysis of randomized controlled trials
Authors: Mamatha Pinninti, Mary T Bausch-Jurken, Jeffrey L Jackson, Tanvir Bajwa, M. Fuad Jan, Suhail Allaqaband
Journal: Circulation (2014)

Background: The efficacy and safety of contemporary self-expanding bare metal Nitinol stents (NS) compared to primary Percutaneous Transluminal Angioplasty (PTA) in the treatment of above-knee femoropopliteal atherosclerotic disease is still controversial. Objective: We sought to evaluate the immediate (procedural success) and intermediate (rate of restenosis and target lesion/vessel revascularization (TLR/TVR) at 1 year) clinical outcomes of primary NS implantation versus primary PTA with bailout stenting in the treatment of above-knee femoropopliteal disease by conducting a meta-analysis of the available randomized controlled trials (RCT). Methods: We searched Medline and Cochrane databases from 1990 to 2014. Risk ratios (RR) and 95% confidence intervals (CI) were calculated using random-effects model. Results: Six RCTs with a total of 827 patients (NS = 443, PTA = 384; average age 68.5 years, males = 562, average lesion length = 8.7cm in NS and 7.7cm in PTA) were analyzed on intention to treat basis. T...
Abstract 2967: Metformin selectively targets tumor initiating cells in erbb-2 overexpressing breast cancer models
Authors: Pei Zhu, Meghan Davis, Amanda Blackwelder, Nora Bachman, Bolin Liu, Susan Edgerton, Leonard L. Williams, Ann D. Thor, Xiaohe Yang
Journal: Cancer Research (2014)

Abstract Metformin is an oral biguanide used for type II diabetes. Epidemiologic studies suggest a link between metformin use and reduced risk of breast and other types of cancers. erbB-2 expressing breast cancer is a subgroup of tumors with poor prognosis. Previous studies demonstrated that metformin is a potent inhibitor of erbB-2 overexpressing breast cancer cells; metformin treatment extends the life span and impedes mammary tumor development in ErbB-2 transgenic mice in vivo. However, the mechanisms of metformin associated anti-tumor activity, especially in prevention models, remain unclear. In this study, we investigated the mechanisms of metformin associated prevention/inhibition of ErbB-2 mediated breast cancer development by focusing on the potential effect of metformin on tumor initiating cells (TICs)/cancer stem cells (CSCs) in the MMTV-erbB-2 transgenic mouse model and its context with existing in vitro models. We report here for the first time that systemic administration of metformin (250 mg/kg/day, ip, between 8- and 18-week of age) selectively inhibits CD61high/CD49fhigh subpopulation, a group of TICs of MMTV-ErbB-2 mammary tumors, in preneoplastic mammary glands. Metformin also inhibited CD61high/CD49fhigh subpopulation in MMTV-erbB-2 tumor-derived cells, which was correlated with their compromised tumor initiation/development in a syngeneic tumor graft model. Molecular analysis indicated that metformin induced downregulation of erbB-2 and EGFR expression and inhibited the phosphorylation of erbB family members, IGF1R, Akt, mTOR and Stat3 in vivo. In vitro data indicate that low doses (1 mM) of metformin inhibited the self-renewal/proliferation of CSCs/TICs in ErbB-2-overexpressing breast cancer cells. We further demonstrated that the expression and activation of ErbB-2 were preferentially increased in CSC/TIC-enriched tumorsphere cells, which promoted their self-renewal/proliferation and rendered them more sensitive to metformin. Our results, especially the in vivo data, provide fundamental support for developing metformin-mediated preventive strategies targeting erbB-2-associated carcinogenesis. Citation Format: Pei Zhu, Meghan Davis, Amanda Blackwelder, Nora Bachman, Bolin Liu, Susan Edgerton, Leonard L. Williams, Ann D. Thor, Xiaohe Yang. Metformin selectively targets tumor initiating cells in erbb-2 overexpressing breast cancer models. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2967. doi:10.1158/1538-7445.AM2014-2967
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with <sup>V600E</sup>BRAF-mutated melanoma.
Authors: P. B. Chapman, A. Hauschild, C. Robert, J. M. G. Larkin, J. B. A. G. Haanen, A. Ribas, D. Hogg, S. O'Day, P. A. Ascierto, A. Testori, P. Lorigan, R. Dummer, J. A. Sosman, C. Garbe, R. J. Lee, K. B. Nolop, B. Nelson, J. Hou, K. T. Flaherty, G. A. McArthur
Journal: Journal of Clinical Oncology (2011)

LBA4 Background: About 50% of melanomas have an activating V600E BRAF mutation which led to the hypothesis that inhibition of the mutated BRAF kinase may be of clinical benefit. Phase I and II trials with vemurafenib (previously PLX4032/RO5185426), an orally available inhibitor of oncogenic BRAF kinase, showed response rates (RR; CR+PR) &gt;50% in V600E BRAF- mutated melanoma patients (pts). We conducted a phase III trial to determine if vemurafenib improved overall survival (OS) and progression-free survival (PFS) in melanoma pts with V600E BRAF mutation. Methods: Pts with previously untreated, unresectable stage IIIC or stage IV melanoma that tested positive for V600E BRAF mutation by the cobas 4800 BRAF V600 Mutation Test were randomized (1:1) to vemurafenib (960 mg po bid) or DTIC (1,000 mg/m 2 , IV, q3w). Randomization was stratified by PS, stage, LDH, and geographic region. Pts were assessed for tumor responses after weeks 6, 12, and then q9 weeks. Co-primary endpoints were OS and PFS on the intent-to-treat population; secondary endpoints included RR, response duration, and safety. Final analysis was planned at 196 deaths. Results: 675 pts were enrolled at 103 centers worldwide between Jan and Dec 2010. Treatment cohorts were well-balanced. At the pre-planned interim analysis (50% of deaths needed for final analysis), the hazard ratios for OS and PFS were 0.37 (95% CI 0.26 to 0.55; p&lt;0.0001) and 0.26 (95% CI 0.20 to 0.33; p&lt;0.0001), respectively, both in favor of vemurafenib. The confirmed RR was 48.4% and 5.5% to vemurafenib and DTIC, respectively, among the 65% of pts evaluable for RR to date. Benefit in OS, PFS, and RR was seen in all subgroups examined. Due to these data, the DTIC cohort has been allowed to cross over to vemurafenib. At the time of data analysis, 66% of vemurafenib pts and 25% DTIC pts were still on treatment. The most common toxicities of vemurafenib were: diarrhea, rash, alopecia, photosensitivity, fatigue, arthralgia, and keratoacanthoma/skin squamous cell carcinoma. Conclusions: Vemurafenib is associated with significantly improved OS and PFS compared to DTIC in pts with previously untreated, V600E BRAF-mutated metastatic melanoma.
Communicable Disease Control: A Volume for the Health Officer and Public Health Nurse
Authors: Gaylord West Anderson, Margaret G. Arnstein
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Age-specific infection and death rates for human A(H5N1) avian influenza in Egypt
Authors: J P Dudley
Journal: Eurosurveillance (2009)

The age-specific infection and death profiles among confirmed human cases of influenza A(H5N1) infection in Egypt differ markedly from those recorded in other countries. The case fatality rate among human H5N1 cases in Egypt is 34%, versus an average of 66% in other countries. In Egypt, children younger than 10 years comprise 48% of reported cases, nearly twice the global average of approximately 25%, and no H5N1 fatalities have been confirmed among individuals in this age group as of 23 April 2009. Females outnumber males among confirmed H5N1 cases by a factor of nearly 2:1, and 90% of reported fatalities in Egypt have been females. The evident age and sex biases in morbidity and mortality among H5N1 cases in Egypt are phenomena that warrant further investigation and analysis.
297. Molecular Analysis of a Severe Adverse Event in the UK SCID-X1 Gene Therapy Clinical Trial
Authors: SJ Howe, M Mansour, M Brugman, K Pike-Overzet, M Hubank, N Jina, D de Ridder, F Staal, C Baum, C Kinnon, HB Gaspar, AJ Thrasher
Journal: Molecular Therapy (2008)